Comparison of breast cancer patients who underwent partial mastectomy (PM) with mini latissimus dorsi flap (MLDF) and subcutaneous mastectomy with implant (M + I) regarding quality of life (QOL), cosmetic outcome and survival rates

Ozmen, Vahit; Ilgun, Serkan; Celet Ozden, Burcu; Ozturk, Alper; Aktepe, Fatma; Agacayak, Filiz; Elbuken, Filiz; Alco, Gul; Ordu, Cetin; Erdogan Iyigun, Zeynep; Emre, Hocaoglu; Pilancı, Kezban; Soybir, Gursel; Ozmen, Tolga

doi:10.1186/s12957-020-01858-z

Table 1 Comparison of patient and tumor characteristics in two groups

From: Comparison of breast cancer patients who underwent partial mastectomy (PM) with mini latissimus dorsi flap (MLDF) and subcutaneous mastectomy with implant (M + I) regarding quality of life (QOL), cosmetic outcome and survival rates

Characteristics		Group 1	Group 2	pvalue
		(PM + MLDF)	(M + I)
		(n = 242)	(n = 75)
Median age (year)		45 (26–73)	42 (24–78)	0.003^a
BMI (kg/m2)		24.4 (16.4–44.4)	22.5 (16.9–32.4)	0.006^a
Menopausal status
Pre-menopausal		166 (68.6%)	65 (86.7%)	0.002^#
Post-menopausal		76 (31.4%)	10 (13.3%)	0.002^#
Tumor size (mm)		23 (1–90)	20 (1–80)	0.009^a
Breast volume (ml)		537.22 ± 235.52	613.75 ± 253.83	p= 0.253
Tumor focality
Unifocal		177 (74.1%)	37 (50%)	0.000^b
Multifocality/multicentricity		62 (25.9%)	37 (50%)	0.000^b
Tumor Histology
IDC		204 (84.3%)	54 (72%)	0.056^b
ILC		19 (7.9%)	10 (13.3%)
Others		19 (7.9%)	11 (14.7%)
Histologic Grade
HG I		12 (5%)	7 (9.5%)	0.000^b
HG II		92 (38.3%) ^a	46 (62.2%) ^b
HG III		136 (56.7%) ^a	21 (28.4%) ^b
pT Stage
T1		106 (43.8%)	44 (58.7%)	0.052^b
T2		126 (52.1%)	27 (36%)
T3		10 (4.1%)	4 (5.3%)
pN Stage
N0		114 (47.1%)	51 (68%)	0.002^b
N+		128 (52.9%)	24 (32%)	0.002^b
ALND
(+)		126 (52.1%)	25 (33.3%)	0.005^b
(-)		116 (48%)	50 (66.7%)	0.005^b
LVI
(+)		115 (48%)	23 (31.5%)	0.013^b
(-)		125 (52%)	50 (68.5%)	0.013^b
ER
(+)		194 (80.2%)	64 (85.3%)	0.315^b
(-)		48 (19.8%)	11 (14.7%)	0.315^b
PR
(+)		167 (69%)	57 (76%)	0.245^b
(-)		75 (31%)	18 (24%)	0.245^b
HER 2
(+)		52 (21.5%)	15 (20.8%)	0.90^b
(-)		190 (78.5%)	57 (79.2%)	0.90^b
Molecular Subtypes	Luminal A	63 (32%)	31 (49.2%)	0.013^b
	Luminal B	134 (68%)	32 (50.8%)	0.013^b
	HER-2 (+)	15 (33.3%)	6 (50%)	0.28^b
	TNBC	30 (66.7%)	6 (50%)	0.28^b
Surgical morbidity
Yes		41 (17%)	17 (23%)	0.126^b
No		201 (83%)	58 (77%)	0.126^b
5-year overall survival (95% CI)		97% (96.98–97.02)	97% (96.96–97.04)	0.976^c
5-year local recurrence free survival (95% CI)		99% (98.98–99.02)	97% (96.96–97.04)	0.377^c
5-year disease free survival (95% CI)		95% (94.96–95.04)	93% (92.94–93.06)	0.361^c

ER estrogen receptor, PR progesterone receptor, BMI body mass index, IDC invasive ductal carcinoma, TNBC triple negative breast cancer, ALND axillary lymph node dissection, LVI lymphovascular invasion, ILC invasive lobular carcinoma
^aMann Whitney U test
^bChi-square test
^cLog-rank

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us